Elanco Animal Health Inc ELAN
Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine and sheep (collectively, farm animal). Our purpose – making life better for animals makes life better – inspires us to Go Beyond for animals, our customers, our people and society.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B | $3.27B | $3.07B | $3.07B | $2.89B | $2.91B |
| Cost of revenue | $2.12B | $2.00B | $1.93B | $1.91B | $2.13B | $1.67B | $1.47B | $1.57B | $1.49B | $1.41B |
| Gross profit | $2.59B | $2.44B | $2.49B | $2.50B | $2.63B | $1.60B | $1.60B | $1.49B | $1.40B | $1.50B |
| R&D | $368.0M | $344.0M | $327.0M | $321.0M | $369.0M | $329.0M | $270.0M | $246.6M | $251.7M | $265.8M |
| SG&A | $1.43B | $1.31B | $1.28B | $1.26B | $1.40B | $997.0M | $760.0M | $735.2M | $779.8M | $784.8M |
| Total operating expenses | — | $3.95B | $5.61B | $4.48B | $5.33B | $3.95B | $2.99B | $2.95B | $3.12B | $2.94B |
| Interest expense | — | — | $277.0M | $241.0M | $236.0M | $150.0M | $79.0M | $29.6M | $0 | $0 |
| Pre-tax income | -$224.0M | $488.0M | -$1.20B | -$72.0M | -$571.0M | -$677.0M | $78.0M | $114.1M | -$232.6M | -$22.4M |
| Income tax | $8.0M | $150.0M | $36.0M | $6.0M | $88.0M | $103.0M | $10.0M | $27.6M | $78.1M | $25.5M |
| Net income | -$232.0M | $338.0M | -$1.23B | -$78.0M | -$483.0M | -$574.0M | $68.0M | $86.5M | -$310.7M | -$47.9M |
| EPS, basic | -0.47 | 0.68 | -2.50 | -0.16 | -0.99 | -1.30 | 0.18 | 0.28 | -1.06 | — |
| EPS, diluted | -0.47 | 0.68 | -2.50 | -0.16 | -0.99 | -1.30 | 0.18 | 0.28 | -1.06 | -0.16 |
| Shares, diluted (wtd. avg.) | $496.4M | $497.3M | $492.3M | $488.3M | $487.2M | $441.4M | $370.3M | $313.7M | $293.3M | $293.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M | $506.0M | $345.0M | $678.0M | $323.4M | $258.8M |
| Receivables | $873.0M | $805.0M | $842.0M | $797.0M | $833.0M | $872.0M | $816.9M | $651.8M | $567.4M | — |
| Inventory | $1.74B | $1.57B | $1.74B | $1.54B | $1.37B | $1.58B | $1.05B | $1.00B | $1.06B | — |
| Total current assets | $3.46B | $3.21B | $3.41B | $3.28B | $3.27B | $3.42B | $2.37B | $2.50B | $2.12B | — |
| Property, plant and equipment | — | $993.0M | $1.03B | $999.0M | $1.05B | $1.32B | $955.3M | $922.4M | $920.3M | — |
| Goodwill | $4.78B | $4.41B | $5.09B | $5.99B | $6.17B | $6.22B | $2.99B | $2.96B | $2.97B | — |
| Other intangibles | $3.41B | $3.68B | $4.49B | $4.84B | $5.59B | $6.39B | $2.48B | $2.50B | $2.67B | — |
| Total assets | $13.36B | $12.61B | $14.36B | $15.49B | $16.48B | $17.69B | $8.99B | $8.96B | $8.94B | — |
| Accounts payable | $368.0M | $296.0M | $270.0M | $390.0M | $416.0M | $501.0M | $222.6M | $205.2M | $203.8M | — |
| Short-term debt | — | $44.0M | $38.0M | $388.0M | $294.0M | $555.0M | $24.5M | $29.0M | $0 | — |
| Total current liabilities | $1.60B | $1.31B | $1.24B | $1.70B | $1.65B | $2.08B | $818.5M | $970.7M | $643.1M | — |
| Long-term debt | $3.76B | $4.32B | $5.74B | $5.45B | $6.03B | $5.57B | $2.33B | $2.44B | $0 | — |
| Total liabilities | $6.81B | $6.52B | $8.14B | $8.20B | $8.97B | $9.22B | $3.44B | $3.76B | $1.16B | — |
| Retained earnings | -$2.18B | -$1.95B | -$2.29B | -$1.06B | -$979.0M | -$477.0M | $84.3M | $16.4M | $0 | — |
| Total equity | $6.55B | $6.10B | $6.22B | $7.29B | $7.51B | $8.46B | $5.54B | $5.20B | $7.78B | $7.02B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M | -$41.0M | $224.0M | $487.3M | $173.8M | $155.9M |
| Depreciation and amortisation | $680.0M | $662.0M | $694.0M | $682.0M | $716.0M | $517.0M | $314.0M | $296.0M | $318.4M | $254.4M |
| Stock-based compensation | $68.0M | $55.0M | $46.0M | $59.0M | $66.0M | $47.0M | $49.0M | $26.0M | $25.0M | $20.4M |
| Capital expenditure | $276.0M | $147.0M | $140.0M | $171.0M | $159.0M | $135.0M | $140.0M | $134.5M | $98.6M | $110.3M |
| Investing cash flow | -$279.0M | $1.16B | -$169.0M | -$179.0M | -$530.0M | -$4.78B | -$235.0M | -$127.0M | -$964.6M | -$182.1M |
| Financing cash flow | -$275.0M | -$1.49B | -$83.0M | -$549.0M | $210.0M | $4.95B | -$305.0M | -$35.2M | $847.5M | -$149.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001739104-26-000016.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |